Allianz Biotechnologie A EUR/  DE0008481862  /

Fonds
NAV2/20/2024 Chg.-0.9000 Type of yield Investment Focus Investment company
215.9100EUR -0.42% paying dividend Equity Worldwide Allianz Gl.Investors 

Investment strategy

The Fund aims to generate long-term capital growth. We invest at least 70% of the Fund"s assets directly or via derivatives in equities and comparable securities of companies whose principal activity is researching, developing and producing biotechnological goods, processes or services. We may invest up to 10% of the Fund"s assets in Chinese A-shares. Moreover, investments can also be made in other equities and comparable securities. Up to 30% of the Fund"s assets may also be invested in money market instruments or bank deposits. A maximum of 10% of the Fund"s assets may be invested in target funds (UCITS and/or UCI). We pursue an active management approach aimed at outperforming the benchmark. The benchmark index is used for performance measurement purposes only and not for the purpose of portfolio composition. The majority of the securities included in the Fund are also included in the benchmark index. The fund manager has the flexibility to invest in securities that are not included in the benchmark index. When selecting and weighting the Fund's assets, Fund Management may deviate significantly from the securities included in the benchmark index, as well as their corresponding weightings. Benchmark: NASDAQ Biotechnology Price (in EUR).
 

Investment goal

The Fund aims to generate long-term capital growth. We invest at least 70% of the Fund"s assets directly or via derivatives in equities and comparable securities of companies whose principal activity is researching, developing and producing biotechnological goods, processes or services. We may invest up to 10% of the Fund"s assets in Chinese A-shares. Moreover, investments can also be made in other equities and comparable securities. Up to 30% of the Fund"s assets may also be invested in money market instruments or bank deposits. A maximum of 10% of the Fund"s assets may be invested in target funds (UCITS and/or UCI).
 

Master data

Type of yield: paying dividend
Funds Category: Equity
Region: Worldwide
Branch: Sector Biotechnology
Benchmark: NASDAQ Biotechnology Price (in EUR)
Business year start: 1/1
Last Distribution: 3/6/2023
Depository bank: State Street Bank International GmbH
Fund domicile: Germany
Distribution permission: Austria, Germany
Fund manager: Chris Chin
Fund volume: 295.05 mill.  EUR
Launch date: 1/9/1998
Investment focus: -

Conditions

Issue surcharge: 6.00%
Max. Administration Fee: 1.75%
Minimum investment: 0.00 EUR
Deposit fees: -
Redemption charge: 0.00%
Key Investor Information: Download (Print version)
 

Investment company

Funds company: Allianz Gl.Investors
Address: Bockenheimer Landstraße 42-44, 60323, Frankfurt am Main
Country: Germany
Internet: www.allianzgi.com
 

Assets

Stocks
 
96.87%
Cash
 
3.13%

Countries

United States of America
 
87.64%
United Kingdom
 
4.97%
Netherlands
 
1.42%
Canada
 
0.80%
Denmark
 
0.69%
Switzerland
 
0.46%
Germany
 
0.40%
Costa Rica
 
0.25%
Ireland
 
0.24%
Others
 
3.13%

Branches

Pharma/Biotechnology
 
83.36%
Pharma, production
 
5.77%
Healthcare
 
4.18%
Healthcare products
 
0.57%
Others
 
6.12%